Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
The revised outlook assumes a second-half revenue decline of approximately 68%–74%, versus the prior 64%–74% range.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Organogenesis Holdings (Nasdaq: ORGO) reported third-quarter 2026 net product revenue of $45.5 million, down sharply from the prior year. Revenue fell 70% from $150.5 million, with Advanced Wound Care down 73% and Surgical & Sports Medicine down 19%. Gross margin fell to 52% from 76%. Net loss was $29.6 million, versus net income of $21.6 million; diluted earnings per share moved to a $0.25 loss from $0.11 income.
Nine-month net product revenue fell 63% to $124.5 million, and net loss widened to $179.1 million from $6.7 million. September 30 cash and cash equivalents were $21.326 million, versus $93.679 million at December 31, 2025. The company now expects 2026 revenue of $179.4 million–$200.0 million, down 65%–68% from 2025, with fourth-quarter sequential improvement at a more measured rate than previously assumed.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointThird-quarter selling, general and administrative expenses fell 43% to $45.1 million year over year.
- Minor pointThird-quarter research and development expense fell 40% to $8.0 million year over year.
- Minor pointThird-quarter cost of goods sold fell 40% to $21.9 million year over year.
- Minor pointNine-month selling, general and administrative expenses fell 27% to $164.2 million year over year.
- Minor pointNine-month cost of goods sold fell 19% to $71.3 million year over year.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Organogenesis expects sequential revenue improvement in the fourth quarter, at a more measured rate than previously assumed.
- Minor pointOutstanding debt obligations remained at zero at September 30, 2026.
Negative
- Major pointThird-quarter net product revenue fell 70% to $45.5 million from $150.5 million a year earlier.
- Major pointThird-quarter net results shifted to a $29.6 million loss from $21.6 million income a year earlier.
- Major point. Forward-looking: it has not happened yet and may not happen.Organogenesis now expects 2026 revenue of $179.4 million–$200.0 million, down 65%–68% from $564.2 million in 2025.
- Moderate pointThird-quarter gross profit fell 79% to $23.6 million; gross margin dropped to 52% from 76%.
- Moderate pointThird-quarter operating results shifted to a $29.5 million loss from $20.7 million income a year earlier.
- Moderate pointNine-month research and development expense rose 21% to $41.4 million year over year.
- Moderate pointCash and cash equivalents fell to $21.326 million at September 30, 2026, from $93.679 million at year-end.
19 minor points
- Minor pointAdvanced Wound Care third-quarter revenue fell 73% to $38.2 million year over year.
- Minor pointSurgical & Sports Medicine third-quarter revenue fell 19% to $7.3 million year over year.
- Minor pointThird-quarter diluted EPS shifted to a $0.25 loss from $0.11 income a year earlier.
- Minor pointThird-quarter adjusted net results shifted to a $29.3 million loss from $23.2 million income a year earlier.
- Minor pointThird-quarter adjusted EBITDA shifted to a $22.4 million loss from $30.1 million income a year earlier.
- Minor pointThird-quarter non-GAAP operating results shifted to a $29.1 million loss from $23.0 million income a year earlier.
- Minor pointNine-month net product revenue fell 63% to $124.5 million from $338.0 million a year earlier.
- Minor pointAdvanced Wound Care nine-month revenue fell 67% to $103.780 million year over year.
- Minor pointSurgical & Sports Medicine nine-month revenue fell 13% to $20.732 million year over year.
- Minor pointNine-month gross profit fell 79% to $53.2 million; gross margin dropped to 43% from 74%.
- Minor pointNine-month operating loss widened to $149.4 million from $18.6 million a year earlier.
- Minor pointNine-month net loss widened to $179.1 million from $6.7 million a year earlier.
- Minor pointNine-month diluted loss per share widened to $1.47 from $0.12 a year earlier.
- Minor pointNine-month adjusted net results shifted to a $162.1 million loss from $2.3 million income a year earlier.
- Minor pointNine-month adjusted EBITDA shifted to a $104.9 million loss from $14.0 million income a year earlier.
- Minor pointNine-month non-GAAP operating loss widened to $126.1 million from $6.3 million a year earlier.
- Minor pointStockholders’ equity fell to $119.737 million at September 30, 2026, from $300.129 million at year-end.
- Minor pointNine-month income taxes shifted to a $30.078 million expense from a $9.789 million benefit a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Expected second-half revenue decline is approximately 68%–74% year over year, versus the prior 64%–74% guidance range.
News Explained
During the first nine months of 2026, Organogenesis issued common stock in connection with its ATM facility, net of offering costs. Outstanding common shares were 129,793,728 on
Key Figures
- Net revenue
- $45.5 million; down 70%
- Q3 2026 versus Q3 2025
- Advanced Wound Care revenue
- $38.2 million; down 73%
- Q3 2026 versus Q3 2025
- Net loss
- $29.6 million
- Q3 2026, versus $21.6 million net income in Q3 2025
- Gross margin
- 52%
- Q3 2026, versus 76% in Q3 2025
- FY2026 revenue outlook
- $179.4 million–$200.0 million; projected decline of 65%–68%
- Fiscal year ending December 31, 2026
- Cash, cash equivalents and restricted cash
- $26.9 million
- September 30, 2026; no outstanding debt obligations
Previous Earnings Reports
-
Revenue fell 58% year over year, with a $96.3 million quarterly net loss and lower FY guidance.
-
Revenue declined 58% year over year and net loss reached $53.2 million; FY guidance was reduced.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
non-gaap financial
redeemable convertible preferred stock financial
atm facility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Results Summary:
- Net revenue of
$45.5 million for the third quarter of 2026, a decrease of$105.0 million compared to net revenue of$150.5 million for the third quarter of 2025. Net revenue for the third quarter of 2026 consists of:- Net revenue from Advanced Wound Care products of
$38.2 million , a decrease of73% from the third quarter of 2025. - Net revenue from Surgical & Sports Medicine products of
$7.3 million , a decrease of19% from the third quarter of 2025.
- Net revenue from Advanced Wound Care products of
- Net loss of
$29.6 million for the third quarter of 2026, compared to net income of$21.6 million for the third quarter of 2025, an increase in net loss of$51.2 million . - Adjusted net loss of
$29.3 million for the third quarter of 2026, compared to adjusted net income of$23.2 million for the third quarter of 2025, an increase in adjusted net loss of$52.5 million . - Adjusted EBITDA loss of
$22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of$30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of$52.5 million .
“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”
Third Quarter 2026 Financial Results:
| Three Months Ended September 30, | Change | ||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||
| (in thousands, except for percentages) | |||||||||||||||
| Advanced Wound Care | $ | 38,152 | $ | 141,451 | $ | (103,299 | ) | (73 | %) | ||||||
| Surgical & Sports Medicine | 7,305 | 9,036 | (1,731 | ) | (19 | %) | |||||||||
| Net product revenue | $ | 45,457 | $ | 150,487 | $ | (105,030 | ) | (70 | %) | ||||||
Net product revenue for the third quarter of 2026 was
Gross profit for the third quarter of 2026 was
Operating expenses for the third quarter of 2026 were
Operating loss for the third quarter of 2026 was
Total other expense, net, for the third quarter of 2026 was
Net loss for the third quarter of 2026 was
Adjusted net loss was
Adjusted EBITDA loss was
Non-GAAP operating loss was
Nine Months Ended September 30, 2026 Financial Results:
| Nine Months Ended September 30, | Change | ||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||
| (in thousands, except for percentages) | |||||||||||||||
| Advanced Wound Care | $ | 103,780 | $ | 314,074 | $ | (210,294 | ) | (67 | %) | ||||||
| Surgical & Sports Medicine | 20,732 | 23,885 | (3,153 | ) | (13 | %) | |||||||||
| Net product revenue | $ | 124,512 | $ | 337,959 | $ | (213,447 | ) | (63 | %) | ||||||
Net product revenue for the nine months ended September 30, 2026 was
Gross profit for the nine months ended September 30, 2026 was
Operating expenses for the nine months ended September 30, 2026 were
Operating loss for the nine months ended September 30, 2026 was
Total other income, net, for the nine months ended September 30, 2026 was
Net loss for the nine months ended September 30, 2026 was
Adjusted net loss was
Adjusted EBITDA loss was
Non-GAAP operating loss was
As of September 30, 2026, the Company had
Fiscal Year 2026 Outlook:
For the year ending December 31, 2026, the Company now expects:
- Total net revenue between
$179.4 million and$200.0 million , representing a decline in the range of65% to68% , as compared to total net revenue of$564.2 million for the year ended December 31, 2025.- Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the fourth quarter, however, at a more measured rate versus what our prior guidance assumed, resulting in a second half revenue decline in the range of approximately
68% to74% year over year, and compared to our prior guidance range which assumed a decline in the range of64% to74% year-over-year.
- Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the fourth quarter, however, at a more measured rate versus what our prior guidance assumed, resulting in a second half revenue decline in the range of approximately
Third Quarter Earnings Conference Call:
Management will host a conference call at 5:00 p.m. Eastern Time on November 5th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
| ORGANOGENESIS HOLDINGS INC. | |||||||
| UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (amounts in thousands, except share and per share data) | |||||||
| September 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 21,326 | $ | 93,679 | |||
| Restricted cash | 163 | 652 | |||||
| Accounts receivable, net | 92,687 | 217,451 | |||||
| Inventories, net | 26,683 | 29,627 | |||||
| Asset held for sale | — | 2,425 | |||||
| Prepaid expenses and other current assets | 17,268 | 18,354 | |||||
| Total current assets | 158,127 | 362,188 | |||||
| Property and equipment, net | 98,600 | 103,711 | |||||
| Intangible assets, net | 2,571 | 9,145 | |||||
| Goodwill | 28,772 | 28,772 | |||||
| Operating lease right-of-use assets, net | 47,808 | 55,749 | |||||
| Deferred tax asset, net | — | 29,962 | |||||
| Other assets | 33,027 | 9,203 | |||||
| Total assets | $ | 368,905 | $ | 598,730 | |||
| Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Current portion of finance lease obligations | $ | 897 | $ | 9,435 | |||
| Current portion of operating lease obligations - related party | 4,846 | 4,258 | |||||
| Current portion of operating lease obligations | 3,569 | 4,949 | |||||
| Accounts payable | 22,478 | 31,949 | |||||
| Accrued expenses and other current liabilities | 15,859 | 49,533 | |||||
| Total current liabilities | 47,649 | 100,124 | |||||
| Finance lease obligations, net of current portion | 10,372 | 12,788 | |||||
| Operating lease obligations, net of current portion - related party | 24,472 | 28,237 | |||||
| Operating lease obligations, net of current portion | 20,360 | 22,470 | |||||
| Other liabilities | 3,311 | 1,193 | |||||
| Total liabilities | 106,164 | 164,812 | |||||
| Commitments and contingencies (Note 15) | |||||||
| Series A redeemable convertible preferred stock, | 143,004 | 133,789 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 13 | 13 | |||||
| Additional paid-in capital | 302,164 | 303,194 | |||||
| Accumulated deficit | (182,440 | ) | (3,078 | ) | |||
| Total stockholders’ equity | 119,737 | 300,129 | |||||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $ | 368,905 | $ | 598,730 | |||
| ORGANOGENESIS HOLDINGS INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | |||||||||||||||
| (amounts in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue: | |||||||||||||||
| Net product revenue | $ | 45,457 | $ | 150,487 | $ | 124,512 | $ | 337,959 | |||||||
| Grant income | — | 377 | 1,928 | 603 | |||||||||||
| Total revenue | 45,457 | 150,864 | 126,440 | 338,562 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of goods sold | 21,898 | 36,251 | 71,343 | 87,604 | |||||||||||
| Selling, general and administrative | 45,087 | 79,743 | 164,238 | 226,062 | |||||||||||
| Research and development | 7,961 | 13,221 | 41,419 | 34,256 | |||||||||||
| Fair value adjustment to assets held for sale | — | 922 | (1,188 | ) | 9,235 | ||||||||||
| Total operating expenses | 74,946 | 130,137 | 275,812 | 357,157 | |||||||||||
| Income (loss) from operations | (29,489 | ) | 20,727 | (149,372 | ) | (18,595 | ) | ||||||||
| Other income (expense), net: | |||||||||||||||
| Interest income (expense), net | (61 | ) | 415 | 457 | 2,045 | ||||||||||
| Other income (expense), net | (71 | ) | 18 | (59 | ) | 93 | |||||||||
| Total other income (expense), net | (132 | ) | 433 | 398 | 2,138 | ||||||||||
| Net income (loss) before income taxes | (29,621 | ) | 21,160 | (148,974 | ) | (16,457 | ) | ||||||||
| Income tax benefit (expense) | (8 | ) | 407 | (30,078 | ) | 9,789 | |||||||||
| Net income (loss) and comprehensive income (loss) | (29,629 | ) | 21,567 | (179,052 | ) | (6,668 | ) | ||||||||
| Accretion of redeemable convertible preferred stock to redemption value | (181 | ) | (140 | ) | (510 | ) | (390 | ) | |||||||
| Cumulative dividend on redeemable convertible preferred stock | (2,959 | ) | (2,734 | ) | (8,705 | ) | (8,042 | ) | |||||||
| Undistributed earnings allocated to participating redeemable convertible preferred stock | — | (4,168 | ) | — | — | ||||||||||
| Net income (loss) attributable to common stockholders | $ | (32,769 | ) | $ | 14,525 | $ | (188,267 | ) | $ | (15,100 | ) | ||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | (0.25 | ) | $ | 0.11 | $ | (1.47 | ) | $ | (0.12 | ) | ||||
| Diluted | $ | (0.25 | ) | $ | 0.11 | $ | (1.47 | ) | $ | (0.12 | ) | ||||
| Weighted-average common shares outstanding: | |||||||||||||||
| Basic | 128,990,436 | 126,881,709 | 128,489,389 | 126,679,109 | |||||||||||
| Diluted | 128,990,436 | 130,848,995 | 128,489,389 | 126,679,109 | |||||||||||
| ORGANOGENESIS HOLDINGS INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (amounts in thousands, except share and per share data) | |||||||
| Nine Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (179,052 | ) | $ | (6,668 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization | 11,769 | 11,207 | |||||
| Amortization of intangible assets | 6,574 | 2,525 | |||||
| Reduction in the carrying value of right-of-use assets | 7,071 | 6,193 | |||||
| Non-cash interest expense | 211 | 208 | |||||
| Deferred tax expense (benefit) | 29,962 | (6,129 | ) | ||||
| Provision recorded for credit losses | 1,161 | 5,403 | |||||
| Loss on disposal of property and equipment | 723 | 73 | |||||
| Adjustment for excess and obsolete inventories | 12,639 | 7,963 | |||||
| Stock-based compensation | 9,494 | 8,974 | |||||
| Fair value adjustment to assets held for sale | (1,188 | ) | 9,235 | ||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | 123,603 | (64,325 | ) | ||||
| Inventories | (14,746 | ) | (14,954 | ) | |||
| Prepaid expenses and other current assets and other assets | 6,924 | (3,298 | ) | ||||
| Operating leases | (5,798 | ) | (6,302 | ) | |||
| Accounts payable | (6,922 | ) | 643 | ||||
| Accrued expenses and other current liabilities | (31,731 | ) | (1,943 | ) | |||
| Other liabilities | 186 | 1,466 | |||||
| Net cash used in operating activities | (29,120 | ) | (49,729 | ) | |||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | (5,712 | ) | (9,499 | ) | |||
| Sale of asset held for sale | 3,612 | — | |||||
| Net cash used in investing activities | (2,100 | ) | (9,499 | ) | |||
| Cash flows from financing activities: | |||||||
| Payments of withholding taxes in connection with RSUs vesting | (3,050 | ) | (1,798 | ) | |||
| Proceeds from the exercise of stock options | — | 155 | |||||
| Principal repayments of finance lease obligations | (10,598 | ) | (869 | ) | |||
| Issuance of common stock in connection with the ATM facility, net of offering costs | 1,432 | — | |||||
| Construction of landlord assets, net of tenant allowance | (23,958 | ) | (10,039 | ) | |||
| Net cash used in financing activities | (36,174 | ) | (12,551 | ) | |||
| Change in cash, cash equivalents and restricted cash | (67,394 | ) | (71,779 | ) | |||
| Cash, cash equivalents, and restricted cash, beginning of period | 94,331 | 136,151 | |||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 26,937 | $ | 64,372 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Cash paid for income taxes | $ | — | 4,086 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||||
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | $ | 9,215 | $ | 8,432 | |||
| Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $ | (236 | ) | $ | (2,029 | ) | |
| Right-of-use assets obtained through finance lease obligations | $ | (357 | ) | $ | 2,282 | ||
| Right-of-use assets obtained through operating lease obligations | $ | — | $ | 2,388 | |||
| Deemed dividend for anti-dilution adjustment to convertible preferred stock | $ | 310 | $ | — | |||
| Landlord asset additions included in accounts payable and accrued expenses and other current liabilities, net of tenant allowances | $ | 2,909 | $ | 1,925 | |||
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
Adjusted EBITDA
Adjusted EBITDA consists of GAAP net loss excluding: (i) interest (income) expense, net, (ii) income tax (benefit) expense, (iii) depreciation and amortization, (iv) amortization of intangible assets, (v) stock-based compensation expense, and (vi) additional infrequently occurring adjustments described in more detail below.
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (Unaudited, in thousands) | |||||||||||||||
| Net income (loss) | $ | (29,629 | ) | $ | 21,567 | $ | (179,052 | ) | $ | (6,668 | ) | ||||
| Interest (income) expense, net | 61 | (415 | ) | (457 | ) | (2,045 | ) | ||||||||
| Income tax (benefit) expense | 8 | (407 | ) | 30,078 | (9,789 | ) | |||||||||
| Depreciation and amortization | 3,927 | 4,029 | 11,769 | 11,207 | |||||||||||
| Amortization of intangible assets (1) | 433 | 842 | 6,574 | 2,525 | |||||||||||
| EBITDA | (25,200 | ) | 25,616 | (131,088 | ) | (4,770 | ) | ||||||||
| Stock-based compensation expense | 2,806 | 3,065 | 9,494 | 8,974 | |||||||||||
| Inventory write-downs (2) | — | — | 3,327 | — | |||||||||||
| Restructuring charge (3) | — | 516 | 8,957 | 516 | |||||||||||
| Fair value adjustment to assets held for sale (4) | — | 922 | (1,188 | ) | 9,235 | ||||||||||
| R&D program termination costs (5) | — | — | 5,588 | — | |||||||||||
| Adjusted EBITDA | $ | (22,394 | ) | $ | 30,119 | $ | (104,910 | ) | $ | 13,955 | |||||
| (1) | Amount includes |
| (2) | Amount reflects inventory write-down adjustments for excess and obsolete inventory resulting from LCD regulatory changes of |
| (3) | Amount reflects employee severance and benefits as well as other exit costs associated with the Company’s restructuring activities of |
| (4) | Amount reflects the fair value adjustment of a building sold in July 2026 classified as held for sale. |
| (5) | Amount reflects termination costs associated with various R&D programs and vendors. |
Adjusted Net Income (Loss)
Adjusted net loss is defined as GAAP net income (loss) plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below, less the estimated tax on these adjustments.
The following table presents a reconciliation of GAAP net loss to non-GAAP adjusted net income (loss), for the periods presented:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (Unaudited, in thousands) | |||||||||||||||
| Net income (loss) | $ | (29,629 | ) | $ | 21,567 | $ | (179,052 | ) | $ | (6,668 | ) | ||||
| Amortization of intangible assets (1) | 433 | 842 | 6,574 | 2,525 | |||||||||||
| Inventory write-downs (2) | — | — | 3,327 | — | |||||||||||
| Restructuring charge (3) | — | 516 | 8,957 | 516 | |||||||||||
| Fair value adjustment to assets held for sale (4) | — | 922 | (1,188 | ) | 9,235 | ||||||||||
| R&D program termination costs (5) | — | — | 5,588 | — | |||||||||||
| Tax on above | (117 | ) | (616 | ) | (6,280 | ) | (3,315 | ) | |||||||
| Adjusted net income (loss) | $ | (29,313 | ) | $ | 23,231 | $ | (162,074 | ) | $ | 2,293 | |||||
| (1) | Amount includes |
| (2) | Amount reflects inventory write-down adjustments for excess and obsolete inventory resulting from LCD regulatory changes of |
| (3) | Amount reflects employee severance and benefits as well as other exit costs associated with the Company’s restructuring activities of |
| (4) | Amount reflects the fair value adjustment of a building sold in July 2026 classified as held for sale. |
| (5) | Amount reflects termination costs associated with various R&D programs and vendors. |
Non-GAAP Operating Income (Loss)
Non-GAAP operating income (loss) is defined as GAAP income (loss) from operations plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below.
The following table presents a reconciliation of GAAP income (loss) from operations to non-GAAP operating income (loss), for the periods presented:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (Unaudited, in thousands) | |||||||||||||||
| Income (loss) from operations | $ | (29,489 | ) | $ | 20,727 | $ | (149,372 | ) | $ | (18,595 | ) | ||||
| Amortization of intangible assets (1) | 433 | 842 | 6,574 | 2,525 | |||||||||||
| Inventory write-downs (2) | — | — | 3,327 | — | |||||||||||
| Restructuring charge (3) | — | 516 | 8,957 | 516 | |||||||||||
| Fair value adjustment to assets held for sale (4) | — | 922 | (1,188 | ) | 9,235 | ||||||||||
| R&D program termination costs (5) | — | — | 5,588 | — | |||||||||||
| Non-GAAP operating income (loss) | $ | (29,056 | ) | $ | 23,007 | $ | (126,114 | ) | $ | (6,319 | ) | ||||
| (1) | Amount includes |
| (2) | Amount reflects inventory write-down adjustments for excess and obsolete inventory resulting from LCD regulatory changes of |
| (3) | Amount reflects employee severance and benefits as well as other exit costs associated with the Company’s restructuring activities of |
| (4) | Amount reflects the fair value adjustment of a building sold in July 2026 classified as held for sale. |
| (5) | Amount reflects termination costs associated with various R&D programs and vendors. |
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, competitive positioning and long-term opportunities. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company’s products, particularly in light of CMS’ updated 2026 Medicare reimbursement and coverage changes; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred losses in the prior periods and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) the Company’s ability to build out its Smithfield, Rhode Island facility on time and on budget; (11) whether (and on what timeline) the Company is able to obtain regulatory approval for and successfully commercialize Amnuvx; and (12) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2025 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@icrinc.com Press and Media Inquiries: Organogenesis communications@organo.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Organogenesis ORGO's third-quarter 2026 revenue and earnings?
Organogenesis reported $45.5 million in net product revenue and a $29.6 million net loss for the quarter ended September 30, 2026. Revenue fell 70% year over year, compared with $150.5 million in the prior-year quarter. Diluted results shifted to a $0.25 loss per share from $0.11 income per share.
What is Organogenesis ORGO's updated 2026 revenue guidance?
Organogenesis now expects $179.4 million to $200.0 million in total net revenue for the year ending December 31, 2026, a decline of 65% to 68% from $564.2 million in 2025. The company expects sequential fourth-quarter revenue improvement at a more measured rate than its prior guidance assumed.